Halozyme (HALO)CEO sold ~$1.09M

~$1.09M

Approx. value · 9,920 sh @ $109.89

770K

Holds after · shares reported

Traded

Oct 6, 2026

Filed

Oct 8, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Aug 10, 2026InsiderDirector sold ~$167K of HALO shares in the open market
2. Aug 14, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On August 14, 2026, Dannielle Appelhans was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”). Ms. Appelhans was elected to the class of directors with terms ending at the Company’s annual meeting of stockholders in 2028 and was not initially assigned to any Board committee.”
3. Aug 17, 2026Insider · 1 personInsiders: 5 sales (~$2.1M)
4. Aug 18, 2026Insider · 1 personInsiders: 3 sales (~$2.1M)
5. Aug 19, 2026Insider · 1 personInsiders: 3 sales (~$2.1M)
6. Sep 9, 2026Insider · 1 personInsiders: 3 sales (~$2.1M)
7. Sep 10, 2026Insider · 1 personInsiders: 2 sales (~$2.1M)
8. Sep 11, 2026Insider · 1 personInsiders: 2 sales (~$2.1M)
9. Sep 16, 2026Insider · 1 personInsiders: 4 sales (~$2.0M)
10. Sep 22, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 1 more item)
11. Sep 28, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 28, 2026, James Daly was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”). Mr. Daly was elected to the class of directors with terms ending at the Company’s annual meeting of stockholders in 2029 and was not initially assigned to any Board committee.”
12. Oct 1, 2026Insider · 1 personInsiders: 4 sales (~$568K)
13. Oct 6, 2026 · this disclosureInsiderCEO sold ~$1.09M of HALO shares in the open market

What came next

1. Oct 6, 2026Insider · 1 personInsiders: 3 sales (~$1.1M)
2. Oct 7, 2026Insider · 1 personInsiders: 4 sales (~$2.2M)
3. Oct 8, 2026Insider · 1 personInsiders: 4 sales (~$2.2M)

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Halozyme

For Halozyme, OQRO holds 39 insider filings (SEC Form 4 or Form 144) and 15 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its HALO page.

Other recent filings by Helen Torley, PRESIDENT AND CEO

• SEC Form 4 at Halozyme (HALO)Oct 8, 2026
• SEC Form 4 at Halozyme (HALO)Oct 8, 2026
• SEC Form 4 at Halozyme (HALO)Oct 8, 2026
• SEC Form 4 at Halozyme (HALO)Oct 8, 2026
• SEC Form 4 at Halozyme (HALO)Oct 8, 2026

The full history of Helen Torley, PRESIDENT AND CEO is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Halozyme

• SEC Form 4Oct 8, 2026
• SEC Form 4Oct 8, 2026
• SEC Form 4Oct 8, 2026
• SEC Form 4Oct 8, 2026
• SEC Form 4Oct 8, 2026
• SEC Form 4Oct 8, 2026

Everything OQRO holds on this company is on its HALO page.